1. AUTOLOGOUS STEM CELL TRANSPLANTATION MAY POTENTIALLY ABROGATE THE NEGATIVE PROGNOSTIC EFFECT OF EARLY RELAPSE AFTER CHEMO OR INMUNOCHEMOTHERAPY IN FOLLICULAR LYMPHOMA. (June 2017) Authors: Jiménez Ubieto, A.; Grande, C.; Caballero, D.; Yañez, L.; Novelli, S.; Hernández‐Garcia, M.; Manzanares, M.; Arranz, R.; Ferreiro, J.; Bobillo, S.; Mercadal, S.; Galego, A.; López‐Jiménez, J.; Moraleda, J.; Vallejo, C.; Albo, C.; Pérez‐Ceballos, E.; Marrero, C.; Magnano, L.; Palomera, L. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 221 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. BENDAMUSTINE AS PART OF CONDITIONING REGIMEN FOR AUTOLOGOUS STEM‐CELL TRANSPLANTATION IN PATIENTS WITH AGGRESSIVE LYMPHOMAS: FINAL ANALYSIS OF A PHASE 2 STUDY FROM GELTAMO. (June 2017) Authors: Martín, A.; Redondo, A.M.; Valcárcel, D.; González, A.P.; Suárez‐Lledó, M.; Bello, J.L.; Canales, M.; Gayoso, J.; Conde, E.; Jarque, I.; del Campo, R.; Arranz, R.; Terol, M.J.; Rifón, J.; Rodríguez, M.J.; Ramírez, M.J.; Castro, N.; Sánchez, A.; López‐Jiménez, J.; Briones, J. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 192 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. LONG‐TERM RESULTS OF THE MULTICENTER PHASE II TRIAL WITH BENDAMUSTINE AND RITUXIMAB AS FIRST LINE TREATMENT FOR PATIENTS WITH MALT LYMPHOMA (MALT‐2008‐01). (June 2017) Authors: Salar, A.; Domingo‐Domenech, E.; Panizo, C.; Nicolás, C.; Bargay, J.; Muntañola, A.; Canales, M.; Bello, J.; Sancho, J.; Tomás, J.; Rodriguez, M.; Peñalver, F.J.; Palomera, L.; Grande, C.; Sánchez‐Blanco, J.J.; Arranz, R.; Conde, E.; Garcia, M.; García, J.F.; Caballero, D. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PHASE 2 RANDOMIZED TRIAL COMPARING STANDARD RCHOP VERSUS BRCAP AS FIRST LINE TREATMENT IN YOUNG PATIENTS WITH HIGH‐RISK DLBCL. A STUDY FROM SPANISH GROUP GELTAMO. (June 2017) Authors: Gonzalez‐Barca, E.; Carrillo, E.; Grande, C.; Martín, A.; Montes‐Moreno, S.; Coronado, M.; Mercadal, S.; Roncero, J.M.; Perez De Oteyza, J.; Nicolas, C.; Rodriguez‐Salazar, M.J.; Sancho, J.M.; Palomera, L.; Lopez, J.; Albo, C.; Peñalver, F.J.; Hernandez, J.A.; Lopez‐Guillermo, A.; Ramirez, M.J.; ... Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 188 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗